在阿尔茨海默病中蛋白酶激活受体4 (PAR4) 基因表达升高预测认知能力下降
Rebecca L Winfree1, Kevin Erreger2, Jared Phillips3
1Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA.
Neurobiology of aging
|May 18, 2024
概括
与蛋白酶激活受体4 (PAR4) 相关的F2RL3 mRNA升高表明阿尔茨海默病 (AD) 风险较高和认知能力下降. 这种基因表达与炎症相关,并预测认知能力恶化,即使考虑到AD病理.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 免疫学 免疫学 免疫学
背景情况:
- 通过蛋白酶激活受体4 (PAR4) 和血栓激活血小板激活会启动级联,导致纤维素沉积,微心脏病发作,血脑屏障破坏和炎症.
- 阿尔茨海默氏病 (AD) 的发病过程涉及复杂的炎症和血管过程.
研究的目的:
- 研究PAR4基因F2RL3的mRNA表达与认知障碍或痴呆症患者和没有认知障碍或痴呆症患者的认知表现之间的关联.
- 探索F2RL3表达,AD神经病理和促炎标志物之间的关系.
主要方法:
- 从参与宗教秩序研究 (ROS) 和急性记忆和衰老项目 (MAP) 的参与者的人类大脑组织中分析F2RL3mRNA表达.
- 全球认知表现的评估和F2RL3表达与临床AD诊断,神经病理学和炎症标志物 (TNFα,IL-1β,NFκB,纤维素原) 的转录水平的相关性.
主要成果:
- 在阿尔茨海默病 (AD) 病例中,F2RL3 mRNA表达升高.
- 较高的F2RL3表达与较差的纵向认知表现和预测的认知衰退有关,独立于AD神经病理.
- F2RL3表达与亲炎性标志物和纤维素原的转录水平呈正相关性.
结论:
- F2RL3 mRNA表达与多种AD相关的结果显著相关,包括认知衰退和炎症.
- F2RL3的编码产物PAR4可能在阿尔茨海默病的发病过程中发挥关键作用.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.3K
04:22Author Spotlight: Exploring Sex-Specific Glial Signatures and Therapeutic Leads for Alzheimer's Disease
Published on: May 20, 2024
822
相关概念视频
01:26Alzheimer's Disease: Overview
465
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
465
01:22Alzheimer's Disease: Treatment
180
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
180